Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 21, 2026

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

1.1K

[In vivo CAR-Ts, a significant breakthrough].

Bertrand Jordan1

  • 1Biologiste, généticien, Président d'Aprogène (association pour la promotion de la génomique), Marseille, France.

Medecine Sciences : M/S
|March 20, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[DNA informs on ancient partner choice].

Medecine sciences : M/S·2026
Same author

[TimeVaults provide recordings of past cellular activity].

Medecine sciences : M/S·2026
Same author

[House of cards?]

Medecine sciences : M/S·2026
Same author

[Towards gene therapy for Hutington's disease].

Medecine sciences : M/S·2025
Same author

[DNA reveals the living world].

Medecine sciences : M/S·2025
Same author

[Human DNA sequencing: from a slightly disappointing holy grail to a commonplace yet essential tool].

Medecine sciences : M/S·2025
Same journal

[CREPT: An ally of immunotherapy for the fight against non-small-cell lung cancers].

Medecine sciences : M/S·2026
Same journal

[A new regulatory mechanism of HIF-1α: the ROS-ATM-CHK2 axis at the core of tumor angiogenesis].

Medecine sciences : M/S·2026
Same journal

[Vibrio-host interactions: from the environmental niche to virulence].

Medecine sciences : M/S·2026
Same journal

[RcsF, hyperconnected sentinel of the bacterial envelope].

Medecine sciences : M/S·2026
Same journal

[Single-cell RNA-sequencing: shattering the clone myth].

Medecine sciences : M/S·2026
Same journal

[No, Physarum blobs do not have 720 sexes!]

Medecine sciences : M/S·2026
See all related articles

A new in vivo chimeric antigen receptor T-cell (CAR-T) therapy transforms T cells within the body, offering a simpler, faster, and more affordable alternative to complex ex vivo CAR-T treatments for B cell malignancies and autoimmune diseases.

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncoimmunology

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy, established in 2017, has shown significant success in treating B cell malignancies.
  • Current ex vivo CAR-T approaches are complex and costly, limiting widespread application.

Purpose of the Study:

  • To introduce and evaluate a novel in vivo method for CAR-T cell generation.
  • To explore the potential of this new approach for treating B cell malignancies and autoimmune diseases.

Main Methods:

  • In situ (in vivo) transformation of T lymphocytes into CAR-T cells.
  • Evaluation of simplicity, speed, and affordability compared to ex vivo methods.

Main Results:

  • The in vivo method offers a promising alternative to traditional ex vivo CAR-T therapy.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

1.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.5K
  • This approach demonstrates potential applicability to autoimmune diseases.

    • Conclusions:

    • In vivo CAR-T generation presents a simplified, faster, and more affordable therapeutic strategy.
    • This innovative method is attracting significant interest in both academic and corporate research environments.